Printer Friendly

Glaucomatous Optic Nerve Changes and Thyroid Dysfunction in an Urban South Korean Population.

1. Introduction

Glaucoma is a chronic optic neuropathy caused by a variety of risk factors and characterized by the progressive loss of retinal ganglion cells (RGC). Intraocular pressure (IOP) is the most important risk factor; however, glaucoma can occur in a low IOP state, and glaucomatous progression can occur during IOP-lowering therapy [1-4]. Therefore, many studies have been conducted to investigate risk factors including IOP and other risk factors [5-7].

Hormones might affect the development of glaucoma and IOP through various mechanisms, and some studies have reported that thyroid hormone affects IOP. Thyroid hormones play a key role in metabolism and homeostasis [8]. Thyroid-associated ophthalmopathy has been described clinically; however, the relationship between thyroid function and glaucoma has remained controversial [9]. Some studies have reported a significant relationship, while others have not. Forte et al. [10] suggested that ocular hypertension (OHT) patients with Graves' orbitopathy showed diffuse abnormalities of the VF and RNFL thinning.

Few studies have been conducted to reveal the relationship between thyroid dysfunction and glaucoma based on the large number of participants. The relationship between thyroid dysfunction and glaucoma is still under debate. In this study, we evaluated the association between IOP, glaucomatous optic nerve change, and thyroid dysfunction.

2. Materials and Methods

This study was conducted in two Kangbuk Samsung Hospital Screening Centers in Seoul and Suwon, South Korea, and followed a retrospective, cross-sectional design. This study followed the tenets of the Declaration of Helsinki and was approved by the institutional review board/ethics committee of Kangbuk Samsung Hospital. The study population consisted of individuals who participated in a comprehensive health screening programme at Kangbuk Samsung Hospital, Seoul, Korea. The purpose of this screening programme was to promote health through early detection of chronic diseases and their risk factors. In addition, the Korean Industrial Safety and Health Law requires working individuals to participate in an annual or a biennial health examination. About 60% of the participants were employees of companies or local governmental organizations and their spouses. The remaining participants registered individually for the programme [11]. Subjects who underwent health screening from August 2012 to July 2013 and who were 20 years or older were enrolled in this study. Systemic examinations, including laboratory tests and sociodemographic and behavioural questionnaires, were administered to all subjects, and their medical histories were reviewed to determine the presence of associated systemic disease. Digital fundus images were collected with a digital fundus camera (CR6-45NM; Canon Inc., Tokyo, Japan). IOP was measured twice in each subject using a noncontact tonometer (TX-F; Canon Inc., Tokyo, Japan), and the mean value of two IOP readings was recorded. In cases of both eyes eligible, the right eye from each subject was considered in statistical analysis. Normal subjects were defined as the persons who did not show any glaucoma/glaucoma suspect findings in the fundus and did not have any medical or surgical history to effect on IOP including thyroid orbitopathy. Diabetes is diagnosed as previous diagnosis or treatment history and fasting plasma glucose level [greater than or equal to] 7.0mmol/L (126mg/dL). Hypertension is diagnosed as a systolic blood pressure [greater than or equal to] 140 mmHg, a diastolic blood pressure [greater than or equal to] 90 mmHg, or current use of antihypertensive drugs. Hyperlipidaemia is diagnosed as abnormally elevated serum level of any or all lipids and/or lipoproteins. We all excluded glaucoma/glaucoma suspect patients and subjects who underwent glaucoma surgery or laser treatment from normal subjects. In glaucoma participants, data from the eyes with glaucoma were used. All fundus photographs were reviewed by two ophthalmologists, two glaucoma specialists, and one retina specialist who were all blinded to demographic features and laboratory findings. The grading was performed independently by ophthalmologists. Any discrepancies among the observers were resolved by consensus between two glaucoma specialists. First, each fundus photograph was classified into one of the two categories based on disc and RNFL appearance: nonglaucomatous or glaucomatous. A glaucomatous RNFL defect was defined as a localized wedge-shaped RNFL defect within 60 degrees running toward or touching the optic disc border. Nonglaucomatous RNFL defects included superior segmental optic hypoplasia and slit defect. A patient was defined as having a glaucomatous optic neuropathy if the vertical cup-disc ratio (VCDR) was [greater than or equal to]0.7 or if the VCDR asymmetry between the right and left eyes was [greater than or equal to]0.2. In cases with newly detected glaucomatous features, glaucoma evaluations were recommended and some of them were determined to have glaucoma or not after undergoing glaucoma evaluation at the hospital. Finally, subjects who had not been previously diagnosed with glaucoma or had not visited a hospital for glaucoma evaluation were placed into either category 2 or 3, according to the criteria set forth by the International Society of Geographical and Epidemiological Ophthalmology (ISGEO) [12]. Category 1 requires a VF defect consistent with glaucoma and either a vertical cupdisc ratio (VCDR) [greater than or equal to] 0.7 (97.5th percentile) or [greater than or equal to]0.2 VCDR asymmetry between the right and left eyes (97.5th percentile). Category 2 indicates that the VF results are not definitive, requiring a VCDR [greater than or equal to] 0.9 (99.5th percentile) or VCDR asymmetry [greater than or equal to] 0.3 (99.5th percentile). Category 3 indicates that there are no data available regarding VF testing or optic disc examination; therefore, visual acuity < 3/60 and an IOP greater than the 99.5th percentile for this population (IOP = 21 mmHg) are required.

Optic disc haemorrhage was defined as an isolated haemorrhage on or around the optic disc or in the peripapillary retina within 1-disc diameter. Subjects with alternative causes of retinal haemorrhage, such as ischemic optic neuropathy, papillitis, retinal vein occlusion, diabetic retinopathy, or posterior vitreous detachment, were excluded. We also excluded participants with low-quality fundus photographs due to media opacity or a small pupil in order to discriminate glaucoma patients, as well as patients who underwent glaucoma surgery and laser treatment and who were on systemic medications that could affect IOP, such as a [beta]-blocker.

Subjects were divided equally into four groups (quartiles) based on thyroid laboratory testing as follows: thyroid-stimulating hormone (TSH, [mu]IU/mL) quartiles, Q1 (TSH < 1.30), Q2 (1.30 [less than or equal to] TSH <1.90), Q3 (1.90 [less than or equal to] TSH < 2.75), and Q4 (TSH [greater than or equal to] 2.75); free thyroxine (free T4, ng/dL) quartiles, Q1 (free T4 < 1.15), Q2 (1.15 [less than or equal to] free T4 < 1.26), Q3 (1.26 [less than or equal to] free T4 < 1.38), and Q4 (free T4 [greater than or equal to] 1.38); and triiodothyronine (T3, pg/mL) quartiles, Q1 (T3 < 2.87), Q2 (2.87 [less than or equal to] T3 < 3.12), Q3 (3.12 [less than or equal to] T3 < 3.40), and Q4 (T3 [greater than or equal to] 3.40). This dividing analysis method was used to it at previous study with blood chemistry data [13]. History of thyroid abnormalities and newly diagnosed subjects were classified into hypothyroidism, hyperthyroidism, thyroid nodular cyst, and thyroid hormone treatment.

All statistical analyses were performed with PASW Statistics 18.0 (IBM, Armonk, New York, USA). Each variable was initially evaluated using the chi-square test, and significant variables (p <01) were included in multivariate logistic regression. Multivariate logistic regression with stepwise selection while controlling for all confounding variables (p < 01) was used to evaluate the independent risk factors associated with glaucoma. Odds ratios (OR) with 95% confidence intervals (CI) were estimated using logistic regression models. In all cases, a p <0.05 was considered statistically significant.

3. Results

Of 168,044 patients treated at the two screening centers, 164,029 (97.61%) were enrolled in this study. The remaining 4015 subjects were excluded because fundus photographs could not be obtained or because low-quality photographs could not be reliably evaluated due to media opacity or small pupil. Of the 164,029 participants, 93,559 (57.0%) were male and 70,470 (43.0%) were female. The mean age was 40.56 [+ or -] 8.51 years. Optic disc haemorrhage was noted in 226 (0.14%) subjects. Of the total 164,029 participants, glaucomatous fundus photographs were obtained in 2454 (1.50%) subjects (apart from the ISGEO criteria, according to the results of optic disc and RNFL appearance in fundus photographs). 1477 subjects (60.2%) of 2454 had been previously diagnosed with glaucoma. Of the remaining 977 subjects, 313 subjects underwent glaucoma evaluations including red-free fundus photography, optical coherence tomography, and visual field testing in our glaucoma clinic. Among these 313 subjects, 162 and 128 were diagnosed as having definite and suspected glaucoma (early glaucoma with RNFL defect), respectively, whereas the remaining 23 did not have glaucoma. The remaining 664 subjects were considered to have glaucoma according to the ISGEO criteria and/or presence of RNFL defect. Glaucoma evaluation including visual field test was not available in 664 subjects; therefore, subjects were diagnosed as ISGEO category 3 (visual acuity < 3/60 and an IOP greater than the 99.5th percentile for this population are required). All eligible cases for glaucoma group showed RNFL defect. The demographic data are shown in Table 1.

On univariate analysis, there was a significant difference in T3 level (p < 0.001, chi-square test) between patients with and without glaucomatous optic neuropathy (Table 2). There was no relationship between disc haemorrhage and thyroid function on univariate analysis. The relationship between thyroid function and IOP was shown in Tables 3 and 4. On univariate analysis of normal population, as the quartile of free T4 and T3 increased, the IOP tended to increase slightly. On multivariate analysis adjusted for age, sex, and comorbidities (diabetes, hypertension, hyperlipidaemia, and current smoker), however, the IOP in the first quartile of free T4 and T3 were higher than the second or other quartiles significantly (Table 5). In analysis of the odds ratio between thyroid dysfunction and glaucoma, thyroid function was not associated with glaucoma (Tables 6 and 7).

4. Discussion

Thyroid hormone affects the maintenance of homeostasis in the body and regulates the basal body metabolism [8]. Many studies have tried to determine the association between hypothyroidism and glaucoma. In our study, we did not find that thyroid dysfunction was an independent risk factor of glaucoma development. On univariate analysis, the presence of glaucomatous optic neuropathy was significantly influenced by the level of T3, but the association did not remain statistically significant on multivariate regression. Disc haemorrhage was not associated with thyroid dysfunction as well.

Considering previous reports about an association between IOP and thyroid function, there was a possible theoretical relationship between thyroid function and glaucoma. Hyperthyroidism might induce IOP increase through increased intraorbital pressure or contraction of enlarged extraocular muscles [14, 15]. The main mechanism could be elevation of episcleral venous pressure secondary to increasing of intraorbital content and pressure. The increased IOP in hypothyroidism could be due to the excessive accumulation of mucopolysaccharides in the trabecular meshwork [16, 17]. Smith et al. [16] reported that the prevalence of hypothyroidism in the primary open-angle glaucoma group was higher than those in the control subjects in their case-control study. They proposed that, in the untreated hypothyroid state, hyaluronic acid accumulates excessively in the trabecular meshwork and/or aqueous, causing an obstruction to facility of outflow. This phenomenon was thought to be due to decreased enzyme activity in the hypothyroid state and decreased degradation of hyaluronic acid. After treatment of hypothyroidism, the outflow of aqueous humor was recovered. Some studies have reported that treating hypothyroidism decreases IOP through increasing aqueous outflow. Centanni et al. [17] reported that the IOP of subjects who showed a significantly higher IOP than the control group of subclinical hypothyroidism were decreased approximately by 3 mmHg after treatment of hypothyroidism. Bahceci et al. [18] reported that hypothyroidism reversibly induced increasing IOP. On the other hand, Cheng and Perkins [19] did not find a statistically significant difference in the distribution of IOP between hypothyroidism and normal control groups. However, their study included thyroid hormone-treated patients, which could have affected the results due to the reversible effects of the treatment. McLenachan and Davies [20] reported that high IOP was associated with hypothyroidism due to changes in the quantity and quality of mucopolysaccharides in the trabecular meshwork.

Physiologically, TSH level and T3 and T4 levels are adjusted in relation to each other [8]. In the hyperthyroid state, blood tests typically show low thyroid-stimulating hormone (TSH) and elevated triiodothyronine (T3) and thyroxine (T4) levels. Otherwise, an elevated TSH indicates that the thyroid gland is not producing enough thyroid hormone (hypothyroid state). In our study, the IOP in the first quartile of free T4 and T3 were higher than those in the second or other quartiles. These results were statistically significant, but the changes were clinically insignificant. These results can be considered the several reasons that might appear. First, this study included a very large number of subjects and the results for each group might be distributed evenly. Due to very large number of the enrolled subjects in the study, statistically significant result was showed. However, the difference was very small and might not be noticeable. Second, in normal population, the structural abnormalities of the extraocular muscles or intraorbital tissues that could affect the IOP were less likely to appear. Therefore, the difference of IOP between groups was less likely to emerge.

Many studies have investigated the association between glaucoma and thyroid dysfunction. In the study of Smith et al. [16], 64 subjects with POAG and 64 controls were evaluated for hypothyroidism. About 23.4% of patients with POAG and 4.7% of controls had hypothyroidism, and the difference was statistically significant. Additionally, in POAG patients, 10.9% showed newly diagnosed hypothyroidism. Munoz-Negrete et al. [21] investigated the prevalence of hypothyroidism in 75 OAG patients and 75 controls. Although applying similar diagnostic criteria as Smith et al. [16], they did not find a statistically significant difference. Gillow et al. [22] investigated this relationship with 100 glaucoma patients using TSH level. Clinical hypothyroidism was present in 4% of participants, and subclinical hypothyroidism was present in 3% of participants. In this study, POAG patients did not show an association with hypothyroidism. Some previous studies about the association between glaucoma and thyroid function were based on their glaucoma diagnosis mainly on IOP, not optic disc evaluation [19, 20, 23, 24].

In the Namil study of Korean subjects, patients with a history of thyroid disease had a 7.4-fold higher risk of open-angle glaucoma than the control group [25]. In the Blue Mountain Eye Study, the incidence of glaucoma was 2.1-fold higher in the thyroxine treatment group than in the control group [26]. Cross et al. [27] reported that the incidence of glaucoma in the thyroid disease group was 1.4-fold higher than in the control group. Lin et al. [28] reported that the hypothyroidism group had a 1.9-fold higher incidence of glaucoma than the control group. Girkin et al. [29] showed significantly higher relative risk of glaucoma in the hypothyroidism group of male subjects that the average age of participants was 69 years.

On the other hand, Karadimas et al. reported a different result. In 100 patients of newly diagnosed hypothyroidism patients, there were no participants with glaucomatous optic nerve damage [30]. Motsko and Jones [31] investigated the risk of OAG with newly diagnosed OAG patients without hypothyroidism. Adjusted for other risk factors, they reported that OAG did not show significant association with hypothyroidism. Haefliger et al. [32] said that glaucoma prevalence does not seem to be significantly increased in thyroid eye disease. Kakigi et al. [33] reported a similar result with us. In this study, participants of National Health Interview Survey were relatively young age (no hypothyroidism; 57.0 [+ or -] 12.5, hypothyroidism; 61.5 [+ or -] 13.3). The unadjusted analysis showed a significant association between self-reported glaucoma and self-reported hypothyroidism. However, multivariate logistic regression analysis adjusted for age, gender, race, comorbidities, and health-related behavior showed no association between self-reported glaucoma and hypothyroidism or thyroid disease. This study was based on two US nationwide surveys and failed to confirm previously reported associations between hypothyroidism and glaucoma.

In some studies for racial characteristics of thyroid eye disease, the effects of thyroid factor on the eyes were different between races [34, 35]. In the study of the effect of smoking, the results showed tendency of higher prevalence of current smokers in subjects with larger orbital muscle volume in normal population [36]. Thyroid hormone might also have an effect on the extraocular muscles [14, 15]. The prevalence of thyroid eye disease between European and Asian populations and the overall risk for Europeans for developing thyroid eye disease were 6.4 times higher than for Asians [34]. The prevalence was 42% in Europeans compared to 7.7% in Asians [34]. Bednarczuk et al. [35] reported that smoking was a risk factor for thyroid eye disease in Polish people but not in Japanese people. There are reports as described above for the extraocular muscles; however, further studies are necessary to support our results. In our study, the percentage of current smoker did not show a significant difference between glaucoma and normal group.

In this study, glaucomatous optic neuropathy did not show a significant correlation with any thyroid factors. The age may be one of the causes of such results. In our study, the mean age of participants was 40.56 years. Other studies that reported the significant associations between glaucoma and thyroid factors had relatively older participants than in our study; the average age of participants was about 63 to 70 years for each study. The old age may have longer duration of thyroid disease than the young age, and thyroid factor may affect to the eye for a longer period of time in the old age. In addition to this, the number of enrolled subjects (164,029) in this study is a very huge data compared to other studies which have been conducted so far. This factor is thought to be able to level the results of statistics between the groups.

There are some limitations in the present study. The number 2431 that finally included in the glaucoma group is the remainder of 2454 which excluded the 23 subjects of nonglaucoma, finally confirmed. Therefore, glaucoma suspect might be included in the glaucoma group. The difference in prevalence of current smokers might influence the results. This study is not a population-based study. Also, patient selection based on participation in serial health screening might be biased toward higher economic and educational levels. Patients who worry about their health undergo medical examinations more frequently and, therefore, tend to be healthier than those who do not undergo frequent examinations. Our study was a cross-sectional study; however, considering the fact that glaucoma is a progressive disease, a longitudinal approach would also provide a valuable data. In addition, we did not perform glaucoma evaluation on all subjects, so it is difficult to fully evaluate the relationships between ophthalmic factors and other general factors. The use of noncontact tonometry rather than applanation tonometry may also be another limitation. Despite these limitations, this study was performed with a large number of participants and targeted a single race. Our data may be helpful to understand the pathophysiology of glaucoma.

In conclusion, our results showed that the IOP tend to be decreased slightly as the quartile of free T4 and T3 increased. However, the clinical significance may be limited. Our study also suggested that thyroid dysfunction was not an independent risk factor of glaucomatous optic neuropathy. These results may increase the understanding of risk factors of glaucoma. Further prospective study is needed to validate the results.

https://doi.org/10.1155/2017/8280209

Conflicts of Interest

No conflicting relationships exist for any author.

References

[1] M. J. Kim, M. J. Kim, H. S. Kim, J. W. Jeoung, and K. H. Park, "Risk factors for open-angle glaucoma with normal baseline intraocular pressure in a young population: the Korea National Health and Nutrition Examination Survey," Clinical & Experimental Ophthalmology, vol. 42, no. 9, pp. 825-832, 2014.

[2] M. Kim, D. M. Kim, K. H. Park, T. W. Kim, J. W. Jeoung, and S. H. Kim, "Intraocular pressure reduction with topical medications and progression of normal-tension glaucoma: a 12-year mean follow-up study," Acta Ophthalmologica, vol. 91, no. 4, pp. e270-e275, 2013.

[3] M. C. Leske, A. Heijl, M. Hussein et al., "Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial," Archives of Ophthalmology, vol. 121, no. 1, pp. 48-56, 2003.

[4] K. Nouri-Mahdavi, D. Hoffman, A. L. Coleman et al., "Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study," Ophthalmology, vol. 111, no. 9, pp. 1627-1635, 2004.

[5] B. Chon, M. Qiu, and S. C. Lin, "Myopia and glaucoma in the South Korean population," Investigative Ophthalmology & Visual Science, vol. 54, no. 10, pp. 6570-6577, 2013.

[6] J. M. Kim, S. H. Kim, K. H. Park, S. Y. Han, and H. S. Shim, "Investigation of the association between Helicobacter pylori infection and normal tension glaucoma," Investigative Ophthalmology & Visual Science, vol. 52, no. 2, pp. 665-668, 2011.

[7] H. S. Kim, K. H. Park, J. W. Jeoung, and J. Park, "Comparison of myopic and nonmyopic disc hemorrhage in primary open-angle glaucoma," Japanese Journal of Ophthalmology, vol. 57, no. 2, pp. 166-171, 2013.

[8] E. A. McAninch and A. C. Bianco, "Thyroid hormone signaling in energy homeostasis and energy metabolism," Annals of the New York Academy of Sciences, vol. 1311, no. 1, pp. 77-87, 2014.

[9] K. I. Woo, Y. D. Kim, and S. Y. Lee, "Prevalence and risk factors for thyroid eye disease among Korean dysthyroid patients," Korean Journal of Ophthalmology, vol. 27, no. 6, pp. 397-404, 2013.

[10] R. Forte, P. Bonavolonta, and P. Vassallo, "Evaluation of retinal nerve fiber layer with optic nerve tracking optical coherence tomography in thyroid-associated orbitopathy," Ophthalmologica, vol. 224, no. 2, pp. 116-121, 2010.

[11] K. C. Sung, S. Ryu, Y. Chang, C. D. Byrne, and S. H. Kim, "C-reactive protein and risk of cardiovascular and all-cause mortality in 268 803 East Asians," European Heart Journal, vol. 35, no. 27, pp. 1809-1816, 2014.

[12] P. J. Foster, R. Buhrmann, H. A. Quigley, and G. J. Johnson, "The definition and classification of glaucoma in prevalence surveys," The British Journal ofOphthalmology, vol. 86, no. 2, pp. 238-242, 2002.

[13] H. T. Kim, J. M. Kim, J. H. Kim et al., "The relationship between vitamin D and glaucoma: a Kangbuk Samsung Health Study," Korean Journal of Ophthalmology, vol. 30, no. 6, pp. 426-433, 2016.

[14] K. Ohtsuka and Y. Nakamura, "Open-angle glaucoma associated with Graves disease," American Journal of Ophthalmology, vol. 129, no. 5, pp. 613-617, 2000.

[15] H. B. Lee, I. R. Rodgers, and J. J. Woog, "Evaluation and management of Graves' orbitopathy," Otolaryngologic Clinics of North America, vol. 39, no. 5, pp. 923-942, 2006, vi.

[16] K. D. Smith, B. P. Arthurs, and N. Saheb, "An association between hypothyroidism and primary open-angle glaucoma," Ophthalmology, vol. 100, no. 10, pp. 1580-1584, 1993.

[17] M. Centanni, R. Cesareo, O. Verallo et al., "Reversible increase of intraocular pressure in subclinical hypothyroid patients," European Journal of Endocrinology, vol. 136, no. 6, pp. 595-598, 1997.

[18] U. A. Bahceci, S. Ozdek, Z. Pehlivanli, I. Yetkin, and M. Onol, "Changes in intraocular pressure and corneal and retinal nerve fiber layer thicknesses in hypothyroidism," European Journal of Ophthalmology, vol. 15, no. 5, pp. 556-561, 2005.

[19] H. Cheng and E. S. Perkins, "Thyroid disease and glaucoma," The British Journal of Ophthalmology, vol. 51, no. 8, pp. 547-553, 1967.

[20] J. McLenachan and D. M. Davies, "Glaucoma and the thyroid," The British Journal of Ophthalmology, vol. 49, no. 8, pp. 441-444, 1965.

[21] F. J. Munoz-Negrete, G. Rebolleda, F. Almodovar, B. Diaz, and C. Varela, "Hypothyroidism and primary open-angle glaucoma," Ophthalmologica, vol. 214, no. 5, pp. 347-349, 2000.

[22] J. T. Gillow, P. Shah, and E. C. O'Neill, "Primary open angle glaucoma and hypothyroidism: chance or true association?" Eye (London, England), vol. 11, no. Pt 1, pp. 113-114, 1997.

[23] K. D. Smith, G. J. Tevaarwerk, and L. H. Allen, "An ocular dynamic study supporting the hypothesis that hypothyroidism is a treatable cause of secondary open-angle glaucoma," Canadian Journal of Ophthalmology, vol. 27, no. 7, pp. 341-344, 1992.

[24] T. Krupin, L. S. Jacobs, S. M. Podos, and B. Becker, "Thyroid function and the intraocular pressure response to topical corticosteroids," American Journal of Ophthalmology, vol. 83, no. 5, pp. 643-646, 1977.

[25] M. Kim, T. W. Kim, K. H. Park, and J. M. Kim, "Risk factors for primary open-angle glaucoma in South Korea: the Namil study," Japanese Journal of Ophthalmology, vol. 56, no. 4, pp. 324-329, 2012.

[26] A. J. Lee, E. Rochtchina, J. J. Wang, P. R. Healey, and P. Mitchell, "Open-angle glaucoma and systemic thyroid disease in an older population: The Blue Mountains Eye Study," Eye (London, England), vol. 18, no. 6, pp. 600-608, 2004.

[27] J. M. Cross, C. A. Girkin, C. Owsley, and G. McGwin Jr., "The association between thyroid problems and glaucoma," The British Journal of Ophthalmology, vol. 92, no. 11, pp. 1503-1505, 2008.

[28] H. C. Lin, J. H. Kang, Y. D. Jiang, and J. D. Ho, "Hypothyroidism and the risk of developing open-angle glaucoma: a five-year population-based follow-up study," Ophthalmology, vol. 117, no. 10, pp. 1960-1966, 2010.

[29] C. A. Girkin, G. McGwin Jr., S. F. McNeal, P. P. Lee, and C. Owsley, "Hypothyroidism and the development of open-angle glaucoma in a male population," Ophthalmology, vol. 111, no. 9, pp. 1649-1652, 2004.

[30] P. Karadimas, E. A. Bouzas, F. Topouzis, D. A. Koutras, and G. Mastorakos, "Hypothyroidism and glaucoma. A study of 100 hypothyroid patients," American Journal of Ophthalmology, vol. 131, no. 1, pp. 126-128, 2001.

[31] S. P. Motsko and J. K. Jones, "Is there an association between hypothyroidism and open-angle glaucoma in an elderly population? An epidemiologic study," Ophthalmology, vol. 115, no. 9, pp. 1581-1584, 2008.

[32] I. O. Haefliger, G. von Arx, and A. R. Pimentel, "Pathophysiology of intraocular pressure increase and glaucoma prevalence in thyroid eye disease: a mini-review," Klinische Monatsblatter fur Augenheilkunde, vol. 227, no. 4, pp. 292-293, 2010.

[33] C. Kakigi, T. Kasuga, S. Y. Wang et al., "Hypothyroidism and glaucoma in the United States," PloS One, vol. 10, no. 7, e0133688 pages, 2015.

[34] M. Tellez, J. Cooper, and C. Edmonds, "Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin," Clinical Endocrinology, vol. 36, no. 3, pp. 291-294, 1992.

[35] T. Bednarczuk, Y. Hiromatsu, T. Fukutani et al., "Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations," European Journal of Endocrinology, vol. 148, no. 1, pp. 13-18, 2003.

[36] N. I. Regensburg, W. M. Wiersinga, T. T. Berendschot, P. Saeed, and M. P. Mourits, "Effect of smoking on orbital fat and muscle volume in Graves' orbitopathy," Thyroid, vol. 21, no. 2, pp. 177-181, 2011.

Yu Sam Won, (1) Da Yeong Kim, (2) and Joon Mo Kim (2)

(1) Department of Neurosurgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

(2) Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Correspondence should be addressed to Joon Mo Kim; kjoonmo1@gmail.com

Received 1 December 2016; Revised 23 January 2017; Accepted 15 February 2017; Published 2 May 2017

Academic Editor: Terri L. Young
Table 1: Demographic and general health characteristics.

Characteristics                    Glaucoma (+) (n = 2431)

Age, years (mean [+ or -] SD)        44.10 [+ or -] 9.17
Male (%)                                 1736 (71.4%)
IOP (mmHg)                            15.8 [+ or -] 3.1
Diabetes (%)                              157 (6.5)
Hypertension (%)                          497 (20.4)
Hyperlipidaemia (%)                       473 (19.5)
Current smoker (%)                        547 (22.5)
TSH ([mu]IU/mL)                       2.39 [+ or -] 3.64
Free T4 (ng/dL)                       1.27 [+ or -] 0.25
T3 (pg/mL)                            3.21 [+ or -] 0.84
Hyperthyroidism (%)                       37 (1.5%)
Hypothyroidism (%)                        36 (1.5%)
Nodular cyst (%)                          138 (5.6%)
Hormone treatment (%)                     48 (2.0%)
Characteristic                  Disc haemorrhage (+) (n = 226)
Age, years (mean [+ or -] SD)        44.68 [+ or -] 8.97
Male (%)                                 151 (66.81%)

Characteristics                     Glaucoma (-) (n = 161 598)

Age, years (mean [+ or -] SD)          40.50 [+ or -] 8.50
Male (%)                                  91,823 (56.8%)
IOP (mmHg)                              15.0 [+ or -] 3.0
Diabetes (%)                                4732 (2.9)
Hypertension (%)                           13,998 (8.7)
Hyperlipidaemia (%)                       22,332 (13.8)
Current smoker (%)                        33,158 (20.5)
TSH ([mu]IU/mL)                         2.26 [+ or -] 2.67
Free T4 (ng/dL)                         1.26 [+ or -] 0.23
T3 (pg/mL)                             3.162 [+ or -] 0.65
Hyperthyroidism (%)                        2752 (1.7%)
Hypothyroidism (%)                         3086 (1.9%)
Nodular cyst (%)                          11,239 (6.7%)
Hormone treatment (%)                      3081 (1.8%)
Characteristic                  Disc haemorrhage (-) (n = 163,803)
Age, years (mean [+ or -] SD)          40.55 [+ or -] 8.51
Male (%)                                 93,408 (57.02%)

Characteristics                 p value

Age, years (mean [+ or -] SD)   <0.001*
Male (%)                        <0.001**
IOP (mmHg)                      <0.001*
Diabetes (%)                    <0.001**
Hypertension (%)                <0.001**
Hyperlipidaemia (%)             <0.001**
Current smoker (%)              0.033**
TSH ([mu]IU/mL)                  0.089*
Free T4 (ng/dL)                  0.080*
T3 (pg/mL)                      <0.001*
Hyperthyroidism (%)             <0.001**
Hypothyroidism (%)              <0.001**
Nodular cyst (%)                <0.001**
Hormone treatment (%)           <0.001**
Characteristic                  p value
Age, years (mean [+ or -] SD)   <0.001*
Male (%)                        0.003**

Continuous values are presented as mean [+ or -] standard
deviation (SD).

Categorical values are presented as percentage (%).

* Student's t-test, ** Chi-square test.

Table 2: Univariate analysis of glaucoma and thyroid function.

                             1st quartile     Quartiles of thyroid
                                                      hormone

Glaucoma (+)                                2nd quartile   3rd quartile
(n = 2431)

  TSH ([mu]IU/mL)            635 (25.93%)   612 (24.99%)   604 (24.66%)
  (n = 2449) (0.01 ~ 100)
  Free T4 (ng/dL)            583 (23.87%)   638 (26.13%)   625 (25.59%)
  (n = 2442) (0.06 ~ 7.70)
  T3 (pg/mL)                 438 (21.09%)   461 (22.20%)   612 (29.47%)
  (n = 2077)
  (0.34 ~ 32.60)

                             4th quartile   p value

Glaucoma (+)
(n = 2431)

  TSH ([mu]IU/mL)            598 (24.42%)   0.943*
  (n = 2449) (0.01 ~ 100)
  Free T4 (ng/dL)            596 (24.41%)   0.090*
  (n = 2442) (0.06 ~ 7.70)
  T3 (pg/mL)                 566 (27.25%)   <0.001*
  (n = 2077)
  (0.34 ~ 32.60)

* Chi-square test

TSH: 1st quartile < 1.30, 1.30 [less than or equal to] 2nd quartile
< 1.90, 1.90 [less than or equal to] 3rd quartile < 2.75, 4th
quartile [greater than or equal to] 2.75; free T4: 1st quartile <
1.15, 1.15 < 2nd quartile < 1.26, 1.26 [less than or equal to] 3rd
quartile < 1.38, 4th quartile [greater than or equal to] 1.38; T3:
1st quartile < 2.87, 2.87 [less than or equal to] 2nd quartile <
3.12, 3.12 < 3rd quartile < 3.40, 4th quartile [greater than or
equal to] 3.40.

Table 3: Univariate analysis of thyroid function and IOP in a
normal population without glaucoma.

Variables                             IOP (mmHg)        p value
TSH ([mu]IU/mL)                                         <0.001*
  1st quartile                    14.94 [+ or -] 2.96
  (<1.30) (n = 39,894) (25.91%)
  2nd quartile (1.30-1.90)        15.02 [+ or -] 2.96
  (n = 39,402) (25.58%)
  3rd quartile (1.90-2.75)        15.04 [+ or -] 2.94
  (n = 38,013) (24.68%)
  4th quartile ([greater than     15.02 [+ or -] 2.92
    or equal to] 2.75)
  (n = 36,681) (23.83%)

Free T4 (ng/dL)                                         <0.001*
  1st quartile (<1.15)            14.92 [+ or -] 2.94
  (n = 39,071) (25.43%)
  2nd quartile (1.15-1.26)        15.01 [+ or -] 2.95
  (n = 39,972) (26.01%)
  3rd quartile (1.26-1.38)        15.05 [+ or -] 2.95
  (n = 39,268) (25.55%)
  4th quartile ([greater than     15.05 [+ or -] 2.95
    or equla to] 1.38)
  (n = 35,350) (23.01%)

T3 (pg/mL)                                              <0.001*
  1st quartile (<2.87)            14.64 [+ or -] 2.95
  (n = 33,064) (24.36%)
  2nd quartile (2.87-3.12)        14.88 [+ or -] 2.95
  (n = 31,796) (23.44%)
  3rd quartile (3.12-3.40)        15.10 [+ or -] 2.96
 (n = 35,356) (26.06%)
  4th quartile ([greater than     15.19 [+ or -] 2.96
    or equal to] 3.40)
  (n = 35,466) (26.14%)

Characteristics          (+)                    (-)           p value
of disease

Hypothyroidism    14.65 [+ or -] 2.93   15.01 [+ or -] 2.95   <0.001**
Hyperthyroidism   14.87 [+ or -] 2.92   15.01 [+ or -] 2.95   0.017**
Nodular cyst      14.92 [+ or -] 2.90   15.01 [+ or -] 2.95   0.003**
Hormone           14.82 [+ or -] 2.93    15.01 [+ or -] 2.95  0.001**
  treatment

Continuous values are presented as mean [+ or -] standard
deviation (SD).

* One-way ANOVA, ** Student's t-test.

Table 4: Univariate analysis of thyroid function and IOP in thyroid
disease patients without glaucoma.

Variables                       IOP (mmHg)            p value

TSH ([mu]IU/mL)                                       0.128*
  1st quartile (<1.30)          14.79 [+ or -] 2.92
  (n = 3677) (32.32%)
  2nd quartile (1.30-1.90)      14.80 [+ or -] 2.80
  (n = 1788) (15.72%)
  3rd quartile (1.90-2.75)      14.68 [+ or -] 2.85
  (n = 2020) (17.75%)
  4th quartile ([greater than   14.87 [+ or -] 2.91
    or equal to] 2.75)
  (n = 3891) (34.21%)

Free T4 (ng/dL)                                       0.762*
  1st quartile (<1.15)          14.76 [+ or -] 2.89
  (n = 3755) (33.12%)
  2nd quartile (1.15-1.26)      14.81 [+ or -] 2.85
  (n = 2581) (22.76%)
  3rd quartile (1.26-1.38)      14.81 [+ or -] 2.88
  (n = 2101) (18.53%)
  4th quartile ([greater than   14.84 [+ or -] 2.92
    or equal to] 1.38)
  (n = 2901) (25.59%)

T3 (pg/mL)                                            <0.001*
  1st quartile (<2.87)          14.60 [+ or -] 2.92
  (n = 4171) (41.69%)
  2nd quartile (2.87-3.12)      14.77 [+ or -] 2.86
  (n = 2292) (22.91%)
  3rd quartile (3.12-3.40)      14.95 [+ or -] 2.88
  (n = 1818) (18.17%)
  4th quartile ([greater than   14.90 [+ or -] 2.91
    or equal to] 3.40)
  (n = 1724) (17.23%)

Characteristics            (+)                    (-)           p value
of disease

Hypothyroidism      14.65 [+ or -] 2.90   14.85 [+ or -] 2.88   0.001**
Hyperthyroidism     14.87 [+ or -] 2.94   14.78 [+ or -] 2.87   0.161**
Nodular cyst        14.88 [+ or -] 2.86   14.74 [+ or -] 2.91   0.016**
Hormone treatment   14.86 [+ or -] 2.95   14.78 [+ or -] 2.87   0.191**

Continuous values are presented as mean  [+ or -]  standard
deviation (SD).

* One-way ANOVA, ** Student's t-test.

Table 5: Adjusted coefficients and 95% confidence intervals
of IOP stratified by each thyroid function parameter in a
normal population without glaucoma.

Variables                     Coefficients     95% confidence
                                                   interval

Age                               0.025         (0.024-0.027)
Sex (male)                        0.726         (0.693-0.759)
Diabetes                          0.697         (0.609-0.784)
Hypertension                      0.381         (0.326-0.436)
Hyperlipidaemia                   0.150         (0.106-0.194)
Current smoker                    0.234         (0.194-0.275)
TSH ([mu]IU/mL)
  1st quartile (<1.30)        0 (reference)
  2nd quartile (1.30-1.90)        0.074         (0.033-0.115)
  3rd quartile (1.90-2.75)        0.135         (0.094-0.177)
  4th quartile ([greater          0.159         (0.117-0.200)
    than or equal to] 2.75)

Age                               0.025         (0.023-0.026)
Sex (male)                        0.766         (0.732-0.801)
Diabetes                          0.702         (0.614-0.789)
Hypertension                      0.384         (0.329-0.439)
Hyperlipidaemia                   0.146         (0.102-0.190)
Current smoker                    0.220         (0.180-0.259)
Free T4 (ng/dL)
  1st quartile (<1.15)        0 (reference)
  2nd quartile (1.15-1.26)       -0.025         (-0.066-0.016)
  3rd quartile (1.26-1.38)       -0.087       (-0.129 to -0.044)
  4th quartile ([greater         -0.176       (-0.221 to -0.131)
    than or equal to] 1.38)

Age                               0.025         (0.023-0.027)
Sex (male)                        0.737         (0.702-0.773)
Diabetes                          0.693         (0.606-0.781)
Hypertension                      0.381         (0.326-0.436)
Hyperlipidaemia                   0.152         (0.108-0.196)
Current smoker                    0.216         (0.176-0.256)
T3 (pg/mL)
  1st quartile (<2.87)        0 (reference)
  2nd quartile (2.87-3.12)       -0.102       (-0.143 to -0.060)
  3rd quartile (3.12-3.40)       -0.043       (-0.085 to -0.001)
  4th quartile ([greater         -0.050       (-0.094 to -0.006)
    than or equal to] 1.38)

Hypothyroidism                   -0.091         (-0.200-0.017)
Hyperthyroidism                   0.042         (-0.071-0.156)
Nodular cyst                      0.071         (0.011-0.130)
Hormone treatment                -0.004         (-0.113-0.104)

Variables                     p value*

Age                            <0.001
Sex (male)                     <0.001
Diabetes                       <0.001
Hypertension                   <0.001
Hyperlipidaemia                <0.001
Current smoker                 <0.001
TSH ([mu]IU/mL)
  1st quartile (<1.30)
  2nd quartile (1.30-1.90)     <0.001
  3rd quartile (1.90-2.75)     <0.001
  4th quartile ([greater       <0.001
    than or equal to] 2.75)

Age                            <0.001
Sex (male)                     <0.001
Diabetes                       <0.001
Hypertension                   <0.001
Hyperlipidaemia                <0.001
Current smoker                 <0.001
Free T4 (ng/dL)
  1st quartile (<1.15)
  2nd quartile (1.15-1.26)     0.239
  3rd quartile (1.26-1.38)     <0.001
  4th quartile ([greater       <0.001
    than or equal to] 1.38)

Age                            <0.001
Sex (male)                     <0.001
Diabetes                       <0.001
Hypertension                   <0.001
Hyperlipidaemia                <0.001
Current smoker                 <0.001
T3 (pg/mL)
  1st quartile (<2.87)
  2nd quartile (2.87-3.12)     <0.001
  3rd quartile (3.12-3.40)     0.045
  4th quartile ([greater       0.027
    than or equal to] 1.38)

Hypothyroidism                 0.099
Hyperthyroidism                0.465
Nodular cyst                   0.019
Hormone treatment              0.938

Adjusted for age, sex, diabetes, hypertension, hyperlipidaemia,
and current smoker.

Diabetes is diagnosed as previous diagnosis or treatment history of
diabetes or fasting plasma glucose level [greater than or equal to]
7.0 mmol/L (126 mg/dL).

Hypertension is diagnosed as a systolic blood pressure [greater than
or equal to] 140 mmHg, a diastolic blood pressure [greater than or
equal to] 90 mmHg, or current use of antihypertensive drugs.

Hyperlipidaemia is diagnosed as abnormally elevated serum level of any
or all lipids and/or lipoproteins.

* Multivariate linear regression analysis.

Table 6: Adjusted odds ratio and 95% confidence
intervals of glaucoma stratified by thyroid function.

Variables                      Odds ratio

Age                               1.029
Sex (male)                        1.783
Diabetes                          1.087
Hypertension                      1.860
Hyperlipidaemia                   0.963
Current smoker                    0.878

T3 (pg/mL)
  1st quartile (<2.87)        1 (reference)
  2nd quartile (2.87-3.12)        1.008
  3rd quartile (3.12-3.40)        1.134
  4th quartile ([greater          1.036
    than or equal to] 3.40)

T3 (pg/mL)
  1st quartile (<2.87)        1 (reference)
  2nd quartile (2.87-3.12)        0.912
  3rd quartile (3.12-3.40)        1.065
  4th quartile ([greater          0.966
    than or equal to] 3.40)

T3 (pg/mL)
  1st quartile (<2.87)        1 (reference)
  2nd quartile (2.87-3.12)        1.071
  3rd quartile (3.12-3.40)        1.153
  4th quartile ([greater          1.056
    than or equal to] 3.40)

T3 (pg/mL)
  1st quartile (<2.87)        1 (reference)
  2nd quartile (2.87-3.12)        0.823
  3rd quartile (3.12-3.40)        1.200
  4th quartile ([greater          1.086
    than or equal to] 3.40)

Variables                      95% confidence interval     p value*

Age                                 (1.024-1.035)           <0.001
Sex (male)                          (1.583-2.007)           <0.001
Diabetes                            (0.878-1.345)           0.445
Hypertension                        (1.632-21,192)          <0.001
Hyperlipidaemia                     (0.850-1.090)           0.547
Current smoker                      (0.781-0.988)           0.031

T3 (pg/mL)                          (All subjects)
  1st quartile (<2.87)
  2nd quartile (2.87-3.12)          (0.873-1.164)           0.915
  3rd quartile (3.12-3.40)          (0.984-1.306)           0.082
  4th quartile ([greater            (0.892-1.203)           0.646
    than or equal to] 3.40)

T3 (pg/mL)                      (20 ~ 39 age subjects)
  1st quartile (<2.87)
  2nd quartile (2.87-3.12)          (0.697-1.193)           0.500
  3rd quartile (3.12-3.40)          (0.822-1.380)           0.634
  4th quartile ([greater            (0.740-1.260)           0.797
    than or equal to] 3.40)

T3 (pg/mL)                      (40 ~ 59 age subjects)
  1st quartile (<2.87)
  2nd quartile (2.87-3.12)          (0.895-1.282)           0.452
  3rd quartile (3.12-3.40)          (0.962-1.381)           0.123
  4th quartile ([greater            (0.871-1.280)           0.581
    than or equal to] 3.40)

T3 (pg/mL)                    (60 or older age subjects)
  1st quartile (<2.87)
  2nd quartile (2.87-3.12)          (0.467-1.450)           0.500
  3rd quartile (3.12-3.40)          (0.695-2.070)           0.514
  4th quartile ([greater            (0.565-2.087)           0.804
    than or equal to] 3.40)

Adjusted for age, sex, diabetes, hypertension, hyperlipidaemia, and
current smoker.

Characteristics of disease (hypothyroidism, hyperthyroidism,
nodular cyst, hormone treatment) include both medical history
review and currently diagnosed disease.

Diabetes is diagnosed as fasting plasma glucose level [greater than
or equal to] 7.0 mmol/L (126 mg/dL).

Hypertension is diagnosed as a systolic blood pressure [greater
than or equal to] 140 mmHg, a diastolic blood pressure [greater
than or equal to] 90 mmHg, or current use of antihypertensive
drugs.
Hyperlipidaemia is diagnosed as abnormally elevated serum
level of any or all lipids and/or lipoproteins.

* Multivariate logistic regression analysis.

Table 7: The odds ratio between thyroid factors and glaucoma.

Variables           Glaucoma (+)     (-)     Odds ratio      95% CI

Hyperthyroidism                                0.905      (0.653-1.255)
(+) (n = 2789)           37         2752
(-) (n = 163,361)       2391       160,970

Hypothyroidism                                 0.783      (0.563-1.091)
(+) (n = 3122)           36         3086
(-) (n = 163,023)       2392       160,631

Nodular cyst                                   0.817      (0.688-0.972)
(+) (n = 11,377)        138        11,239
(+) (n = 154,949)       2293       152,656

Hormone treatment                              1.052      (0.789-1.403)
(+) (n = 3129)           48         3081
(+) (n = 163,079)       2380       160,699

Variables            p *

Hyperthyroidism     0.550
(+) (n = 2789)
(-) (n = 163,361)

Hypothyroidism      0.147
(+) (n = 3122)
(-) (n = 163,023)

Nodular cyst        0.022
(+) (n = 11,377)
(+) (n = 154,949)

Hormone treatment   0.730
(+) (n = 3129)
(+) (n = 163,079)

* Chi-square test.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Won, Yu Sam; Kim, Da Yeong; Kim, Joon Mo
Publication:Journal of Ophthalmology
Article Type:Report
Date:Jan 1, 2017
Words:6911
Previous Article:Prospective 3D Investigation of Bleb Wall after Trabeculectomy Using Anterior-Segment OCT.
Next Article:Enhanced Depth Imaging Optical Coherence Tomography: A New Way Measuring Choroidal Thickness in Pregnant Women.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters